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Background: Plasmodium vivax infections in pregnancy are associated with low birth weight and anaemia. This
parasites species is also characterised by relapses, erythrocytic infections initiated by the activation of the dormant
liver stages, the hypnozoites, to mature. Genotyping of P. vivax using microsatellite markers has opened the way to
comparative investigations of parasite populations. The aim of the study was to assess whether there were any
differences between the parasites found in pregnant and non-pregnant patients, and/or between the admission
infections and recurrent episodes during follow-up.
Methods: Blood samples were collected from 18 pregnant and 18 non-pregnant patients, who had at least two
recurrent episodes during follow-up, that were recruited in two previous trials on the efficacy of chloroquine
treatment of P. vivax infections on the Thai-Myanmar border. DNA was purified and the P. vivax populations
genotyped with respect to eight polymorphic microsatellite markers. Analyses of the genetic diversity, multiplicity
of infection (MOI), and a comparison of the genotypes in the samples from each patient were conducted.
Results: The P. vivax parasites present in the samples exhibited high genetic diversity (6 to 15 distinct allelic
variants found for the 8 loci). Similar expected heterozygosity (He) values were obtained for isolates from pregnant
(0.837) and non-pregnant patients (0.852). There were modest differences between the MOI values calculated for
both admission and recurrence samples from the pregnant patients (2.00 and 2.05, respectively) and the equivalent
samples from the non-pregnant patients (1.67 and 1.64, respectively). Furthermore, the mean number of distinct
alleles enumerated in the admission samples from the pregnant (6.88) and non-pregnant (7.63) patients were
significantly lower than that found in the corresponding recurrent episodes samples (9.25 and 9.63, respectively).
Conclusions: The P. vivax populations circulating in inhabitants along the Thai-Myanmar border, an area of low
malaria transmission, displayed high genetic diversity. A subtle increase in the multiplicity of P. vivax infections in
pregnant patients suggests a higher susceptibility to infection. The higher allelic diversity in the relapse as
compared to the admission samples in both patient groups is consistent with the hypothesis that a febrile episode
promotes the activation of hypnozoites.
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Malaria infection during pregnancy substantially increases
the risk of morbidity and mortality to the mother, her
foetus and the neonate, and thus constitutes an important
public health problem [1]. In areas of high endemicity, the
nefarious effects of infection by Plasmodium falciparum
are most pronounced in primigravidae, and though less
severe, infections in subsequent pregnancies remain asso-
ciated with anaemia and low birth weight [2]. In areas of
low endemicity, the relatively low levels of acquired im-
munity against malaria parasites increase susceptibility to
more severe clinical falciparum episodes during pregnan-
cies, which could result in foetal or maternal death [3].
The impact of infection by Plasmodium vivax, the most
prevalent parasite in the Asia-Pacific region, is less pro-
nounced than that associated with P. falciparum [4]. In a
large-scale study conducted on the western border of
Thailand, an area of low endemicity, P. vivax infections
were more common in primigravidae than in multigrav-
idae and were associated with mild maternal anaemia and
increased risk of low birth weight [5]. Histopathological
examination of the placentas from P. vivax-infected and
treated women did not reveal any evidence of parasite se-
questration or pathological changes [6], thus the patho-
genic mechanisms remain unclear.
One salient biological characteristic of P. vivax is the
formation of dormant liver stages, hypnozoites, by a
proportion of the sporozoites inoculated by the infected
mosquito. Hypnozoites remain uninucleate and meta-
bolically quiescent for varying durations, that can ex-
tend to years, before resuming their development to
form mature schizonts that then initiate a new erythro-
cytic episode upon merozoite release. In tropical areas,
P. vivax infections have a short latent period (2 to
6 weeks), and the primary episode is often followed by a
succession of relapses (every 3 to 4 weeks) that wane in
frequency with time [7]. In the mid 1990’s, the recur-
rence rate for P. vivax infections treated with chloro-
quine and followed up for 63 days was found to be 63%
(95% CI 57-69%) in non pregnant patients on the Thai-
Myanmar border [8]. In a similar study conducted to-
wards the end of the 2000’s in adults and children in the
same region the recurrence rate following chloroquine
treatment increased to 79.1% (95% CI, 73.5%–84.8%),
probably because of increased prevalence of chloro-
quine resistant P. vivax [9]. Indeed, the first case of P.
vivax high-grade resistance to chloroquine in pregnancy
was reported recently from the same area [4]. The only
drug available to eliminate hypnozoites, thus preventing
relapses, is primaquine. Thus, in 1995–1996 when the
first P. vivax recurrence in non pregnant patients on the
Thai-Myanmar border was treated with primaquine and
chloroquine the risk of having a further vivax episode
within 2 months was reduced by 96% (95% CI 83-99%)[8]. However, primaquine is contraindicated in preg-
nancy and in 1986 to 1997 23% (149/634) of pregnant
women had two or more parasitaemia episodes [5].
In recent years, reliable methods to genotype P. vivax
populations using microsatellites have been developed
[10,11]. Using this methodology it was revealed that P.
vivax infections in patients from Thailand, Myanmar and
India are often polyclonal, and that the genotype of the par-
asites in the first relapse following chloroquine treatment
[12] differs from that of the initial admission P. vivax popu-
lation in more than half of the patients. This suggests heter-
ologous activation of hypnozoites, most probably acquired
from earlier inoculations. This was supported by data from
a study of relapses in infants and in their mothers pre- and
post-partum [13] that showed that whereas admission and
relapse infections are often genetically heterologous in the
mothers, those observed in the children are generally
homogeneous. In a recent study P. vivax genetic diversity
was compared in pregnant and non pregnant patients in
Colombia, and found to be similar in both groups [14]. The
purpose of the study presented here is to expand know-
ledge on the genetic diversity of P. vivax in pregnancy be-
yond the few studies quoted above. Given the altered
immunological and physiological status in pregnancy, it
was considered important to ascertain whether the pattern
of relapse and the genetic diversity of the P. vivax popula-
tions observed differed between pregnant and non-
pregnant patients. To this end, a genetic analysis was
conducted on archived samples that had been collected in
the course of drug treatment studies conducted in villages
along the Thai-Myanmar border.
Methods
Study site and collection of blood samples
The studies took place in the Shoklo Malaria Research
Unit clinics on the Thailand-Myanmar border, an area of
low (estimated entomologic inoculation rate of one or
less infectious bites per year) and seasonal malaria trans-
mission [15]. The samples were derived from two previ-
ous trials on the efficacy of chloroquine in the treatment
of P. vivax. The group of P. vivax-infected non-pregnant
women represented all those patients with two relapses
recruited between July 1995 and July 1996 [8], and in
pregnant women recruited between November 1998 and
January 2000 [16]. In both patients groups P. vivax was
confirmed by blood smear and given a treatment with
chloroquine (Government Pharmaceutical Organization,
Thailand) using the following schedule: 15 mg base/kg
on the first day, followed by 5 mg base/kg daily on the
second and third day (total 25 mg base/kg). The non-
pregnant patients were followed up for 63 days and any
recurrent parasitaemia was recorded, treated appropri-
ately and the patient followed up for a further 63 days.
Pregnant patients were followed up until delivery. At
Table 1 Characteristics of pregnant and non-pregnant P. vivax patients
Characteristics Pregnant patients Non-pregnant patients p-value
N = 18 N = 18
Age (years)a 24 ± 7 (15–40) 14 ± 10 (5–46) <0.001
Weight (kg)a 48 ± 6 (41–62) 29 ± 12 (13–48) <0.001
Previous P. vivax malaria
During previous (year)b 5/18 (27.8) 15/18 (83.3) 0.003
>1 episode during previous (year)b 1/5 (20.0) 8/15 (53.3) 0.436
Time since the last episode (days)c 62 (21–102) 65 (36–218) 0.432
Previous P. falciparum
During previous (year)b 4/18 (22.2) 7/18 (38.9) 0.469
>1 episode during previous yearb 1/4 (25.0) 1/7 (14.3) 0.712
Time since the last episode (days)c 26 (21–98) 55 (44–362) 0.088
Characteristics of infection at 1st genotype on day admission N = 18 N = 18
Proportion with a history of feverb 13/18 (72.2) 18/18 (100.0) 0.205
Duration of fever (days)c 3 (1–7) 2 (1–7) 0.016
Proportion febrileb 6/18 (33.3) 10/18 (55.6) 0.314
Temperature (°C)a 37.1 ± 1.4 (35.5-39.7) 37.8 ± 1.0 (36.8-39.9) 0.134
Haematocrit (%)a 32 ± 6 (17–42) 37 ± 3 (31–42) 0.002
Parasitaemia (uL)d 943(32–11,492) 1,991(43–25,844) 0.248
Time to 1st reappearance (days)c 45 (25–71) 43 (35–52) 0.495
Characteristics of patients on day of follow up N = 44 N = 36
Proportion with a history of feverb 22/44 (50.0) 32/36 (88.9) <0.001
Duration of fever in days (range)e 2 (1–3) 1 (1–3) 0.013
Proportion febrileb 11/44 (25.0) 29/36 (80.6) <0.001
Mean temperature (°C)a 36.9 ± 1.1 (35.0-39.7) 38.1 ± 1.0 (35.8-40.8) <0.001
Haematocrit (%)a 31 ± 3 (23–39) 38 ± 3 (30–46) <0.001
Parasitaemia (uL)d 637 (16–3,624) 1,581 (36–22,272) 0.022
Interval times to reappearance (days)
1st reappearance to 2nd reappearance (range)c 51 (28–98) 48 (33–64) 0.468
2nd reappearance to 3rd reappearance (range)c 51(28–66) - -
3rd reappearance to 4th reappearance (range)c 32(28–35) - -
a mean ± SD (min-max).
b Number of patients (%).
c Median (min-max).
d Geometric mean (min-max).
e Range.
N = number of patient.
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that on admission, except in non-pregnant patients where
the second recurrence was treated with chloroquine com-
bined with primaquine (0.25 mg/kg daily for 14 days). The
study in non-pregnant women was approved by the Ethics
Committee of Mahidol University and the Karen Refugee
Committee [8], and that in pregnant women [16] by the
Ethics Committee of the Faculty of Tropical Medicine of
Mahidol University and the Ethics Committee of the
London School of Hygiene & Tropical Medicine. Writteninformed consent was obtained from the patient for the
publication of this report and any accompanying images.
DNA extraction and microsatellite genotyping
The blood samples from the non-pregnant patients were
collected and stored on filter paper (Whatman 3 MM),
while those from the pregnant women were whole blood
with EDTA as anticoagulant stored at −20°C. Genomic
DNA was extracted from a punched out 13 mm diameter
spot for the filter paper samples (equivalent to about 35 μl
Table 2 Genetic diversity of P. vivax infections in pregnant and non-pregnant women based on 8 microsatellite markers














No. of distinct alleles
(A)
P 18 9 9 7 7 6 5 6 6 6.88 1.46 0.52 0.265
NP 18 8 12 9 8 6 4 9 5 7.63 2.56 0.91
He P 18 0.919 0.895 0.889 0.739 0.856 0.772 0.838 0.742 0.831 0.07 0.03 0.533
NP 18 0.876 0.948 0.922 0.830 0.739 0.767 0.892 0.802 0.847 0.07 0.03
No. of distinct alleles
per locus
P 18 1.59 1.61 1.50 1.22 1.56 1.35 1.27 1.38 1.44 0.14 0.05 <0.001
NP 18 1.28 1.33 1.11 1.17 1.22 1.13 1.13 1.07 1.18 0.09 0.03
Recurrent
samples
No. of distinct alleles
(A)
P 44 9 11 10 12 8 6 9 9 9.25 1.83 0.65 0.487
NP 36 13 14 10 11 8 6 8 8 9.63 2.76 0.98
He P 44 0.882 0.824 0.872 0.901 0.846 0.736 0.848 0.839 0.844 0.05 0.02 0.316
NP 36 0.911 0.919 0.884 0.867 0.808 0.783 0.874 0.835 0.86 0.05 0.02
No. of distinct alleles
per locus
P 44 1.49 1.40 1.30 1.50 1.36 1.26 1.27 1.51 1.38 1.11 0.04 <0.001
NP 36 1.26 1.31 1.11 1.17 1.11 1.06 1.10 1.23 1.17 0.09 0.03
All
samples
No of distinct alleles
(A)
P 62 9 12 10 12 8 7 9 10 9.63 1.77 0.63 0.320
NP 54 13 15 10 13 9 6 9 8 10.38 3.02 1.07
He P 62 0.885 0.846 0.869 0.864 0.845 0.736 0.834 0.820 0.837 0.05 0.02 0.340
NP 54 0.906 0.921 0.888 0.848 0.781 0.770 0.866 0.836 0.852 0.06 0.02
No. of distinct alleles
per locus
P 62 1.52 1.46 1.35 1.42 1.42 1.28 1.29 1.47 1.40 0.09 0.03 <0.001
NP 54 1.26 1.31 1.11 1.17 1.15 1.08 1.11 1.18 1.17 0.08 0.03
P = pregnant women and NP = non-pregnant women.
The No. of alleles and He values were calculated from a data set in which only the predominant alleles at each locus was considered.
The No. of alleles per locus values were calculated from all detected alleles at each loci, divided by the total number of samples.
a Paired t-test was used to compare the means between groups.
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blood, using the QiAamp Blood kit (Hilden, Germany)
eluted in a final volume of 100 μl and stored at −20°C
until use. The presence of P. vivax was confirmed in all
the samples by nested PCR [17]. Eight extensively poly-
morphic microsatellite markers: Pv1.501, Pv3.27, Pv3.502,
Pv6.34, Pv 8.504 [10] and MS1, MS5 and MS7 [11], were
used to genotype the isolates using published protocols.
Two microliters of the purified genomic DNA were used
as a template for amplification, and in cases where a sec-
ondary amplification was carried out, it was initiated with
1 μl of the primary amplification product. The amplifiedTable 3 Multiple clone infections and multiplicity of infection
Episodes of infection Pregnant women Non-pregnant women
Samples with multiple clones
Admission 67% 44%
(12/18 isolates) (8/18 isolates)
Recurrence 55% 53%
(24/44 isolates) (19/36 isolates)
All episodes of infection 58% 50%
(36/62 isolates) (27/54 isolates)
*MOI =multiplicity of infection.fragments were analysed on an ABI 3130 Genetic Analyzer
and by GeneMapper® software version 4.0 (Applied
Biosystems) to measure the variable length in the samples.
Data analysis
In any isolate the presence of one or more alleles at a par-
ticular locus was interpreted as a co-infection with two or
more genetically distinct clones, i.e. multiple or polyclonal
infections [10,18]. A locus was classed as having multiple
alleles when the score of the minor peak was at least one-
third the height of the predominant allele present for this
locus. Samples from which the data was ambiguous werein P. vivax
p-
value
Pregnant women Non-pregnant women p-
valueMOI*, mean (±SD)
0.180 2.00 1.67 0.278
(±0.97) (±0.84)
0.875 2.05 1.64 0.110
(±1.41) (±0.80)
0.384 2.03 1.65 0.054
(± 1.30) (±0.81)
Figure 1 Frequency distribution of the number of loci with multiple alleles. The frequency of samples carrying multiple alleles for a given
locus is plotted against the total number of loci in each sample found to be polyclonal.
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units). The genetic diversity was measured using the
predominated allele at each locus to calculate the expected
heterozygosity (He). The formula defined as He = 1/(1-n)
(1-∑pi2) where p is the frequency of ith allele. Expected het-
erozygosity (He) ranges between 0 and 1, a value close to 1






S p-value n IA
S p-value
Single clone Admission 6 0.0250 0.477 10 −0.0236 0.740





Admission 18 0.0007 0.518 18 −0.0045 0.57
Recurrence 40 0.0741 < 1.00 x
10-04




Admission 18 0.0007 0.518 18 −0.0045 0.582
Recurrence 44 0.0865 < 1.00 x
10-04
36 0.0385 1.00 x
10-04[19]. The multiplicity of infection (MOI) was also calcu-
lated as the maximum number of alleles observed at any
locus. Multilocus linkage disequilibrium (LD) was calcu-
lated by using a standardized index of association (ISA)
[20,21]. This test compares the variance (VD) of the num-
ber of alleles shared between all pairs of haplotypes ob-
served in the population (D) with the variance expected
under random association of alleles (VE) as follows: ISA =
(VD/VE-1) (r-1), where r is the number of loci analyzed
[20]. VE is derived from 10,000 simulated data sets in
which alleles were randomly reshuffled among haplotypes.
Significant linkage disequilibrium is detected if VD is
greater than 95% of the values derived from the reshuffled
data sets. Data were analyzed with LIAN 3.1 [22]. Only
the dominant alleles were considered to verify linkage.
In order to detect possible bias due to equivocal assign-
ment of haplotypes in multiple-clone infections, link-
age disequilibrium (LD) was tested at three levels: (i)
for all infections including those with more than one
multi-allelic locus, (ii) for single clone infection, and
(iii) for unique haplotypes only. In order to assess re-
latedness between isolates the genotype observed at
Figure 2 Genotypic relatedness of the P. vivax isolates obtained from individual pregnant (A) and non-pregnant (B) patients. The
number of samples displaying each pattern is provided in the Y-axis. Pairwise comparisons were carried out for all possible combinations. The
samples are coded as follows: Ad = admission, R1 = first recurrence, R2 = second recurrence, R3 = third recurrence, R4 = fourth recurrence. Two
paired samples were classed as genetically different (▲) when the alleles variants differed by more than one repeat unit for at least one locus;
the same if the alleles observed for all the loci are the same in the paired samples (○); and related if all or a subset of the allelic variants detected
in one sample was also observed in the other paired sample. Given that two allelic variants from a given loci can differ by a single repeat unit
because of artefactual slippage during amplification, related genotypes were classed as category “A” ( ) if the allelic variants observed in a
maximum of two loci differed by only by one repeat unit, and “B” (●) if three loci differed as above.
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pared: two genotypes were classed as related if a geno-
type was either a mixture of 2 adjacent microsatellite
alleles at any one locus of which one was present in the
paired sample, or if alleles at one or two loci differed
only by one tandem repeat [13].
Results and discussion
A total of 116 P. vivax isolates were selected for inclusion
in this study: 54 were derived from 18 non-pregnant pa-
tients who all had two recurrent episodes, and 62 were
obtained from 18 pregnant patients who all had two re-
currences, four of whom then had a third and two more a
fourth recurrence. The characteristics of the patients are
provided in Table 1. Non-pregnant patients tended to be
of lower age and to have a more frequent history of P.
vivax infections in the year preceding the date of recruit-
ment to the study than the pregnant patients. They alsotended to have higher temperature and parasitaemia on
admission. As expected, pregnant patients had a lower
haematocrit than non-pregnant patients. The mean inter-
val time to the first reappearance did not significantly dif-
fer between the two groups, 45 days for the pregnant vs
43 days for the non-pregnant patients, nor did it differ for
the second reappearance, 51 days vs 48 days. The second
recurrence in non-pregnant women was treated with
chloroquine and primaquine, and no further recurrences
occurred. In the pregnant women the mean times to the
third and fourth reappearances were 51 days and 32 days,
respectively.
The microsatellite genotyping data were used to calculate
the mean number of distinct alleles (A), the heterozygosity
(He) and the mean number of distinct allelic variants for
each locus in each sample (Table 2). The high number of
distinguishable allelic forms observed for each locus and
the high value of heterozygosity indicated that overall the P.








N = 62 N = 54
No. of recurrent Plasmodium vivax
infections
44 36 0.617
Median number of recurrences
(range)
2 (2–4) 2 (2) 0.221








3rd recurrence and admission
episode similar
3/6 − −
4th recurrence and admission
episode similar
1/2 − −




3rd and 1st recurrence episodes
similar
2/6 − −
3rd and 2nd recurrence episodes
similar
3/6 − −
4th and 1st recurrence episodes
similar
1/2 − −
4th and 2nd recurrence episodes
similar
1/2 − −
4th and 3rd recurrence episodes
similar
1/2 − −
Proportion of genotypically similar
recurrences
27/80 19/54 0.864
In genotypically different recurrence








Criteria for interpretation: A = 1 or 2 markers (loci) different with ≤1 possible
stepwise mutation; B = 3 markers (loci) different but ≤1 repeat unit, different
with ≤1 possible stepwise mutation.
* Chi-square test used to compare in two patients groups.
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gree of genetic diversity. The values did not signifi-
cantly differ between parasites from pregnant and non-
pregnant patients. There was a tendency that did not
reach significance for samples from pregnant women to
have a lower mean number of distinguishable alleles
(A) than those from non-pregnant patients. On the
other hand the number of distinct alleles per locus was
significantly higher in pregnant vs non-pregnant pa-
tients. This was reflected in the higher MOI observed
in the combined admission and recurrence samples
from the pregnant vs non-pregnant women (Table 3), a
difference that nearly reached significance. Nonethe-
less, the proportion of polyclonal infections was not
statistically different between the samples obtainedfrom either group (Table 3). When all the P. vivax sam-
ples from the admission vs the recurrent samples were
compared (Table 2), there was a significant difference
in the mean number of distinct alleles (A) observed for
the loci (7.25 vs 9.5, p-value 0.0001), and the isolates
from the recurrent episodes showed a higher propor-
tion of loci for which more than one allelic variant was
noted in each sample (Figure 1). Linkage disequilibrium
was assessed for clonal infections, infections with unique
haplotype and all infections, in samples from pregnant pa-
tients and non-pregnant patients that were subdivided as
admission and recurrence samples (Table 4). No evident
for linkage disequilibrium was found for the parasites in
the samples obtained on admission, or in the subgroup of
recurrence samples with a monoclonal infection. However,
significant linkage disequilibrium was found for the recur-
rent samples from the two groups when considered in
their entirety or for the subgroup that has a unique haplo-
type (Table 4).
The genetic relatedness of the parasites obtained from
each patient was assessed for all paired combinations
(Figure 2, Table 5). Parasites from the first recurrent epi-
sode were different from those of the admission episode
in 15 of the 18 pregnant patients and in 11 of the 18
non-pregnant patients, and a similar pattern was ob-
served when the second recurrent episode parasites were
compared to those of the first recurrence, in 11/18 and
in 12/18 of the pregnant and non-pregnant patients, re-
spectively. In only 1/18 and 3/18 patients from the two
groups were all the episodes of the same genotype.
It is clear from the analyses above that the P. vivax popu-
lations in this hypoendemic region on the Thai-Myanmar
border exhibited high genetic diversity, with about half of
the isolates harbouring polyclonal infections. The differ-
ences between the parasites present in admission and re-
current samples, or those in pregnant and non-pregnant
patients were relatively subtle. The complexity of the popu-
lations (as assessed by the mean number of distinct alleles
for the 8 microsatellite markers) was higher in the recurrent
as compared to the admission isolates in both groups of pa-
tients. The episodes in pregnant women tended to contain
parasites with a slightly higher mean number of distinct al-
leles per locus and consequently a higher MOI. However,
there are three caveats connected with sampling that need
to be considered before drawing firm conclusions. First,
given the relatively small differences, a higher number of
patients might be needed. Second, the isolates were col-
lected a few years apart. The fact that the parameters of
genetic diversity did not significantly differ between the
two groups of samples, suggests that there was little
change in the extent of the parasites’ genetic diversity
over the periods of sampling (1995–1999), though it is
possible that the genetic diversity in the pregnant
women does not reflect that in the general population.
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plate aliquots used for genotyping was smaller for the
non-pregnant (0.7 μl) than for the pregnant (4 μl) pa-
tients. This was inherent to the nature of the archived
samples (dried blood spots and whole frozen blood, re-
spectively). This six-fold difference in the volume of
blood analyzed might account for the higher MOI in
the pregnant women’s episodes, though it should be
mitigated by the fact that mean parasitaemia in preg-
nant patients was half that in non-pregnant women,
and that a 33% cut-off threshold was used to exclude
the minor alleles. The main reason why this is unlikely
is that it is inconsistent with the increase in allelic di-
versity in recurrent as compared to admission samples.
In conclusion, the parasites causing episodes in pregnant
women had a higher genetic diversity than those in non-
pregnant patients. This could be due to increased suscepti-
bility to mosquito bites, reduced levels of immunity to in-
fection, physiological changes in pregnancy especially if
they affect reticulocyte dynamics, or a combination of these
factors. In both patient groups the parasites at recurrence
following treatment of the admission episode displayed a
higher genetic complexity. In both pregnant and non-
pregnant patients, the parasites at recurrence were genetic-
ally distinct from those on admission in about half the
cases, as were the parasites from the first and the second
recurrence. This pattern is similar to that observed earlier
for relapsing P. vivax episodes in Thailand [12,13]. Differ-
ential accumulation of P. vivax in the placenta has not been
noted in this area [6], though the phenomenon was ob-
served in deliveries at Papua New Guinea [23], and in vitro
cytoadhesion of P. vivax-infected red blood cells to ligands
found in the placenta has been reported [24,25]. However,
at the time when the samples analysed here were obtained,
resistance of P. vivax to chloroquine, the treatment that
was administered to both groups of patients, had not been
recorded in Thailand [8,26]. Therefore, it is highly likely
that the recurrent episodes analysed in this study were re-
lapses originating from hypnozoites. The frequent heterol-
ogous nature of these relapse infections and their increased
genetic diversity as compared to the admission infections
are consistent with the activation of latent hypnozoites hy-
pothesis [27].
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